Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Hyoscine Butyl Bromide for Management of Prolonged Labor

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Status
Patrocinadores
Ain Shams University
Colaboradores
Armed Forces Hospitals, Southern Region, Saudi Arabia

Palavras-chave

Resumo

To determine the value of using Hyoscine as an antispasmodic drug for the management of prolonged labor in nulliparous women at term.

Descrição

Management of prolonged labor represents a challenging area in the daily obstetric practice. In 1993, Handa and Laros defined the arrest of active phase of labor, as failure of labor progress for 2 hours or more, and in 1994, WHO has proposed labor management partograph in which protraction is defined as < 1cm/hour cervical dilatation for a minimum of 4 hours.

Prolong labor increase the risks of maternal exhaustion, postpartum hemorrhage, sepsis, fetal distress and admission to the neonatal intensive care unit. The treatment of prolonged labor is highly desirable goal of intrapartum care, both from prospective of maternal and fetal wellbeing and for the provider of the birth services. Management of prolonged labor entails shorter exposure to pain, anxiety, and stress, and would thus translate into a major improvement in maternal satisfaction with child birth experience.

Several methods have been used for management of prolonged labor including amniotomy and oxytocin. Amniotomy can cause infection, and can be combined with oxytocin for better results while oxytocin can cause uterine hyper stimulation, water intoxication, vomiting, diarrhea, fetal distress, and neonatal jaundice.

Use of antispasmodics for reducing the duration of labor was first described in 1937 by Hirsch, who reported a decrease in labor length by two to four hours following intrapartum administration of an antispasmodic like drug (Syntropan®), mainly among older nulliparous, this was followed by many studies that investigated the role of antispasmodics in prevention of prolonged labor, however none of the these studies assessed the value of the antispasmodic for the treatment of prolonged labor; a recent Cochrane review advised that a rigorously designed well conducted randomized controlled trial with a large sample size would be beneficial to answer the question.

Hyoscine butyl bromide is spasmolytic drug that act by competitive antagonism to acetyl choline at post ganglionic parasympathetic nerve ending. It is claimed to reduce duration of labor by accelerating cervical dilatation without major side effects. It reduces the spasm of the smooth muscles. Although the efficacy of Hyoscine has been proven in various studies there is no clear evidence to recommend their routine use in management of prolonged labor.

The objective of the current study is to determine the use of Hyoscine as an antispasmodic drug for the management of prolonged labor in nulliparous women at term, managed according to a standard intrapartum protocol.

datas

Última verificação: 02/28/2017
Enviado pela primeira vez: 05/10/2013
Inscrição estimada enviada: 05/13/2013
Postado pela primeira vez: 05/14/2013
Última atualização enviada: 03/08/2017
Última atualização postada: 03/09/2017
Data real de início do estudo: 01/31/2014
Data Estimada de Conclusão Primária: 03/31/2017
Data Estimada de Conclusão do Estudo: 05/31/2017

Condição ou doença

Prolonged Labor

Intervenção / tratamento

Drug: Group A

Drug: Group B

Fase

Fase 3

Grupos de Armas

BraçoIntervenção / tratamento
Active Comparator: Group A
Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
Drug: Group A
Placebo Comparator: Group B
Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
Drug: Group B

Critério de eleição

Idades qualificadas para estudar 18 Years Para 18 Years
Sexos elegíveis para estudoFemale
Aceita Voluntários Saudáveissim
Critério

Inclusion Criteria:

- Nulliparous women.

- Prolonged labor defined as no progress of labor for 2 hours or more.

- Gestational age ≥ 37 weeks.

- Singleton pregnancy.

- Cephalic presentation.

- Cervical dilatation ≥ 5 cm.

- Intact fetal membranes.

- No evidence of maternal or fetal distress.

- Average size baby.

Exclusion Criteria:

- Multigravid women.

- Multifetal pregnancy.

- History of cervical surgery.

- Blood pressure > 150/90 mmHg.

- Mal-presentation and mal-positions.

- Hypersensitivity to Hyoscine.

- Contraindication for vaginal delivery.

Resultado

Medidas de Resultado Primário

1. Caesarean section rate for failure to progress [6 hours]

Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge